Nexthera Capital Lp buys $4,826,580 stake in Seattle Genetics (SGEN)

Seattle Genetics (SGEN) : Nexthera Capital Lp scooped up 13,000 additional shares in Seattle Genetics during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 103,000 shares of Seattle Genetics which is valued at $4,826,580.Seattle Genetics makes up approximately 4.72% of Nexthera Capital Lp’s portfolio.

Other Hedge Funds, Including , Wellington Management Group Llp reduced its stake in SGEN by selling 403 shares or 0.68% in the most recent quarter. The Hedge Fund company now holds 59,150 shares of SGEN which is valued at $2,771,769.Manning Napier Advisors reduced its stake in SGEN by selling 60,819 shares or 21.03% in the most recent quarter. The Hedge Fund company now holds 228,321 shares of SGEN which is valued at $10,945,709. Seattle Genetics makes up approx 0.06% of Manning Napier Advisors’s portfolio. Alps Advisors Inc sold out all of its stake in SGEN during the most recent quarter. The investment firm sold 126,124 shares of SGEN which is valued $6,051,430.American Century Companies Inc reduced its stake in SGEN by selling 491 shares or 4.39% in the most recent quarter. The Hedge Fund company now holds 10,691 shares of SGEN which is valued at $512,954.

Seattle Genetics opened for trading at $44.72 and hit $44.97 on the upside on Thursday, eventually ending the session at $44.9, with a gain of 0.79% or 0.35 points. The heightened volatility saw the trading volume jump to 4,40,129 shares. Company has a market cap of $6,309 M.

On the company’s financial health, Seattle Genetics reported $-0.15 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $-0.11. The company had revenue of $111.15 million for the quarter, compared to analysts expectations of $115.99 million. The company’s revenue was up 35.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.17 EPS.

Many Wall Street Analysts have commented on Seattle Genetics. Company shares were Reiterated by Barclays on Jul 27, 2016 to “Overweight”, Firm has raised the Price Target to $ 53 from a previous price target of $48 .Company shares were Reiterated by RBC Capital Mkts on Jul 27, 2016 to “Outperform”, Firm has raised the Price Target to $ 130 from a previous price target of $125 .Company shares were Reiterated by SunTrust on Jul 27, 2016 to “Neutral”, Firm has raised the Price Target to $ 38 from a previous price target of $34 .

Seattle Genetics Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s marketed product ADCETRIS or brentuximab vedotin is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent monomethyl auristatin E (MMAE) utilizing its technology. In addition to ADCETRIS the Company’s pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A SGN-CD19A SGN-LIV1A SGN-CD70A ASG-22ME and ASG-15ME and SEA-CD40 which is based on its sugar-engineered antibody (SEA) technology. In addition it has multiple preclinical and research-stage programs that employ its technologies. Its technologies include ADC technology and Seattle Genetics’ sugar-engineered antibody (SEA) technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *